Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.61 |
| ▸ | CDK1 | P06493 | 7/20 | 0.61 |
| ▸ | ABL1 | P00519 | 8/20 | 0.59 |
| ▸ | PRKCA | P17252 | 5/20 | 0.59 |
| ▸ | SRC | P12931 | 6/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | ABL2 | P42684 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8114880 | 0.99 | EGFR (0.60) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL8579739 | 0.95 | EGFR (0.69) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL6188390 | 0.94 | EGFR (0.57) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL6186182 | 0.94 | EGFR (0.64) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL8578273 | 0.91 | EGFR (0.70) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL6184887 | 0.91 | EGFR (0.55) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL6185513 | 0.88 | EGFR (0.59) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL8124691 | 0.88 | CDK1 (0.76) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL8122065 | 0.87 | EGFR (0.66) | EGFRCDK1ABL1PRKCASRC | |
| SCHEMBL6186191 | 0.86 | EGFR (0.67) | EGFRCDK1ABL1PRKCASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0819129-B1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2000-08-02 | — | — | EP | claimed |
| US-5981533-A | INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR AND CAN BE USED IN THE CASE OF EPIDERMAL HYPERPROLIFERATION (PSORIASIS) AND AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 1999-11-09 | — | — | US | claimed |
| WO-1998014449-A1 | FUSED PYRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | claimed |
| EP-0819129-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-01-21 | — | — | EP | claimed |
| WO-1996031510-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1996-10-10 | — | — | WO | claimed |
| EP-0929553-B1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2005-03-16 | — | — | EP | disclosed |
| US-6251911-B1 | Pyrimidine derivatives and processes for the preparation thereof | NOVARTIS AG (CH) | 2001-06-26 | — | — | US | disclosed |
| EP-0929553-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014450-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| WO-1998014449-A1 | FUSED PYRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |